



CASE D0077 NP

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EL984308376US
Express Mail Label Number

December 17, 2003
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

RAMANATHAN ET AL.

APPLICATION NO: 10/010,568

FILED: DECEMBER 7, 2001

FOR: A NOVEL HUMAN G-PROTEIN COUPLED RECEPTOR,
HGPRBMY23, EXPRESSED HIGHLY IN KIDNEY

Mail Stop DD
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

FEE LETTER FOR INFORMATION DISCLOSURE STATEMENT


Sir:

Please charge Deposit Account No. 19-3880 in the name of Bristol-Myers Squibb Company in the amount of \$180 for payment of the fee pursuant to 37 CFR §1.17(p) for the submission of an Information Disclosure Statement under 37 CFR §1.97(c).

An additional copy of this paper is enclosed. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 19-3880 in the name of Bristol-Myers Squibb Company.

Respectfully submitted,

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
(609) 252-5289
Date: December 17, 2003


Stephen C. D'Amico
Agent for Applicants
Reg. No. 46,652



CASE D0077 NP

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EL984308376US
Express Mail Label Number

December 17, 2003
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

RAMANATHAN ET AL.

APPLICATION NO: 10/010,568

FILED: DECEMBER 7, 2001

FOR: A NOVEL HUMAN G-PROTEIN COUPLED RECEPTOR,
HGPRBM23, EXPRESSED HIGHLY IN KIDNEY

Assistant Commissioner for Patents
Washington, D.C. 20231

FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants believe this paper is being filed before the mailing date of a first Office Action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-3880.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Copies of these references are enclosed herewith.


12/24/2003 MDAMTE1 00000002 193880 10010568

01 FC:1806 180.00 DA

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
(609) 252-5289



Stephen C. D'Amico
Agent for Applicants
Reg. No. 46,652


Date: December 17, 2003

FORM PTO-1449
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE**INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

ATTY. DOCKET NO.
D0077 NP
APPLICATION NO.
10/010,568
APPLICANT
RAMANATHAN ET AL.
FILING DATE
DECEMBER 7, 2001

Group

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
AA						
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						
AK						
AL						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
AM	WO 02/16548	2/28/02	PCT			<input type="checkbox"/>	<input type="checkbox"/>
AN	WO 02/088183	11/7/02	PCT			<input type="checkbox"/>	<input type="checkbox"/>
AO	WO 03/004678	1/16/03	PCT			<input type="checkbox"/>	<input type="checkbox"/>
AP						<input type="checkbox"/>	<input type="checkbox"/>
AQ						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AR	
AS	
AT	

EXAMINER**DATE CONSIDERED**

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.